Kindeva Appoints Shawn Cavanagh to Board of Directors

Kindeva Drug Delivery (Kindeva) announced that Shawn Cavanagh has joined Kindeva’s Board of Directors. The appointment of Mr. Cavanagh is effective as of January 1, 2021. Mr. Cavanagh, with over 30 years of experience in the pharmaceutical services industry, will serve as a valuable and strategic advisor to Kindeva.

Mr. Cavanagh has held senior leadership roles at multiple contract development and manufacturing organizations (CDMOs). He brings to Kindeva a highly relevant set of experiences with global, integrated CDMOs that specialize in innovative and complex drug products. Most recently, he was President, Chief Operating Officer, and member of the Board of Directors at Cambrex Corporation. During his time at Cambrex, Mr. Cavanagh was integral in driving industry-leading growth and ultimately taking the company private in December 2019.

“Shawn’s deep knowledge of the entire drug lifecycle will help Kindeva as we continue to build the industry’s leading complex drug CDMO,” said Aaron Mann, CEO of Kindeva. “I welcome him to our Board of Directors and look forward to working with him on the strategic opportunities in front of Kindeva.”

“Kindeva has a leading reputation in the formulation, development, and commercial supply of complex drugs and combination products,” said Mr. Cavanagh. “I’m excited to support the company as it completes its transition from 3M and continues along its exciting growth trajectory.”

Mr. Cavanagh has also held leadership roles at Lonza, where he served as President of Lonza Bioscience, and Cambrex Bioproducts, a business that was sold by Cambrex to Lonza in 2007. He holds a degree in Chemical Engineering from the University of New Hampshire.

About Kindeva Drug Delivery

Headquartered in St. Paul, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. For more information, visit www.kindevadd.com.